Abstract
The accumulation of abnormal tau protein selectively affects distinct brain regions and specific populations of neurons and glial cells in tau-related dementias, such as Alzheimer’s disease, Pick’s disease and progressive supranuclear palsy. Although the three disorders share the feature of tau protein pathology, the regulatory circuitry of non-coding genetic variants underlying risk-associated cell states remains to be elucidated. Using paired single-nucleus profiling of chromatin accessibility and gene expression across the three conditions, we define cell-type-specific cis-regulatory elements across six cell types and fifty subclasses. Comparing disease-dynamic cis-regulatory elements across three disorders, we find that glia overrepresent disorder-specific gene regulation related to dynamic cellular response to stress. We show that human genetic variants affecting microglial gene regulation converge into distinct and co-regulated modules affecting specific cellular functions. Moreover, polygenic risk modifiers are maximally co-accessible in disorder-specific glial states, modifying distinct pathways such as sphingomyelin regulation in Pick’s disease. Our study informs glial regulators linked to polygenic modifiers of primary tauopathy, establishing modifiable pathways governing resilience.
Similar content being viewed by others
Acknowledgements
We thank Christopher Hartl for sharing Cut&Tag data, Lawrence Chen, Mai Yamakawa, Sen Ma for technical support and coding assistance; Connor Webb for human tissue requesting; Chi Pham Tran for help with IHC experiments, and all lab members for valuable discussions and feedback. We thank Plasmidsaurus for bulk RNA sequencing and data processing and the UCLA Molecular Screening Shared Resource (MSSR) for gRNA transduction of iPSCs. We thank Dr. HyoKyeong Cha, Hayley Fernandes and the UCLA Human Stem Cell and Genome Engineering Center for assistance with iPSC quality control. This work was supported by grants from Rainwater Charitable Foundation (J.E.R), NIH (R01 AG075802 [J.E.R. and L.T.G.], R01 RF1NS128800 [J.E.R.], R01AG068030 [K.J.B], RF1AG065926 [K.J.B and T.R.], R01AG050986 [K.J.B], R01ES033630 [K.J.B], R21AG082014 [K.H.G. and T.B.]) and Ono Pharmaceuticals [J.E.R]. Epigenome Technologies is supported by NIH grant R44AG07969102, which supported the generation of the CUT&Tag dataset used in this study. Institutes of Health (P01AG002132: D.R.S. and Dr. W.F.D). The UCSF Neurodegenerative Disease Brain Bank receives funding support from NIH grants P30AG062422, P01AG019724, U01AG057195, and U19AG063911, as well as the Rainwater Charitable Foundation and the Bluefield Project to Cure FTD.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Dr. Seeley serves as a paid consultant for Lyterian Therapeutics and Trace Neuroscience. The other authors declare they have no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Source data
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Han, X., Rosenberg, G.M., Kisling, V.M. et al. Single-nucleus epigenomic dysregulation unmasks genetic risk-associated neurodegenerative glia states. Nat Commun (2026). https://doi.org/10.1038/s41467-026-73007-1
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41467-026-73007-1


